Biology of the papillomavirus infections. Part III. Immune response;BIOLOGIE DES INFECTIONS A PAPILLOMAVIRUS. III. REPONSE IMMUNITAIRE

Annales de Biologie Clinique

Volumn 56, Issue 3, 1998, Pages 267-276

  Greslin, I ^a   Mougin, C ^a   Seilles, E ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Cervical cancer; Genital immunity; HPV; Papillomavirus

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; VIRUS ANTIBODY;

ANTIGEN PRESENTATION; CANCER RISK; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; NATURAL KILLER CELL; PAPILLOMA VIRUS; PRECANCER; REVIEW; T LYMPHOCYTE; UTERINE CERVIX CANCER; VIRUS INFECTION; VIRUS LATENCY; BIOSYNTHESIS; IMMUNOLOGY; MALE; UTERINE CERVIX TUMOR; VIROLOGY;

ANTIBODIES, VIRAL; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 0031778747     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Mougin C, Bernard B, Lab M. Biologie des infections à papillomavirus. II. Leur rôle dans la carcinogenèse du col utérin. Ann Biol Clin 1998 ; 56 : 21-8.
2. Kraehenbuhl JP, Neutra MR. Molecular and cellular basis of immune protection of mucosal surfaces. Physiol Reviews 1992 ; 72 : 853-79.
3. Zur Hausen H. Papillomavirus in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res 1989 ; 49 : 4677-81.
4. Evander M, Frazer IH, Payne E, Qi YM, Hengst K, McMillan N. Identification of the α6 integrine as a candidate receptor for papillomavirus. J Virol 1997 ; 71 : 5449-59.
5. Parr MB, Parr EL. Mucosal immunity in the female and male reproductive tract. In : Ogra PL, et al. Handbook of mucosal immunology. San Diego, Academy Press 1996 : 677-89.
6. Frazer IH, Tindle R. Cell mediated immunity to papillomavirus. In : Lacey C. Papillomavirus reviews : current research on papillomaviruses. Leeds, Leeds University Press, 1996 : 151-61.
7. Majewski S, Malejczyk J, Jablonska S. The role of cytokines and other factors in HPV infection and HPV-associated tumors. Papillomavirus Report 1996 ; 7 : 143-54.
8. Al Saleh W, Delvenne P, Arrese JE, Nikkels AF, Piérard GE, Boniver J. Inverse modulation of intraepithelial Langerhans' cells and stromal macrophage/dendrocyte populations in human papillomavirus-associated squamous intraepithelial lesions of the cervix. Virchows Arch 1995 ; 427 : 41-8.
9. Morris HH, Gatter KC, Stein H, Mason DY. Langerhans' cells in human cervical epithelium : effects of wart virus infection and intraepithelial neoplasia. Br J Obstet Gynecol 1983 ; 90 : 412-20.
10. Banks L, Moreau F, Vousden K, Pim D, Matlashewski G. Expression of the human papillomavirus E7 oncogene during cell transformation is sufficient to induce susceptibility to lysis by activated macrophages. J Immunol 1991 ; 146 : 2037-42.
11. Keating PJ, Cromme FV, Duggan-Keen M, et al. Frequency of down-regulation of individual HLA-A and B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 1995 ; 146 : 944-52.
12. Cromme F, Snijders PJF, van den Brule AJC, Kenemans P, Meijers CJLM, Walboomers JMM. MHC class I expression in HPV 16 positive cervical carcinomas is posttranscriptionally controlled and independent from c-myc overexpression. Oncogene 1993 ; 8 : 2969-75.
13. Ressing ME, van Driel WJ, Celis E, et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leucocyte antigen-A*0201-restricted E7-encoded epitope. Cancer Res 1996 ; 56 : 582-8.
14. Feltkamp MCW, Vreugdenhil GR, Vierboom MP, et al. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunol 1995 ; 25 : 2638-42.
15. Sheperd PS, Rowe AJ, Cridland JC, Coletart T, Wison P, Luxton JC. Proliferative T cell responses to human papillomavirus type 16 L1 peptides in patients with cervical dysplasia. J Gen Virol 1996 ; 77 : 593-602.
16. Breitburg F, Ramoz N, Salmon J, Orth G. HLA control in the progression of human papillomavirus infections. Sem Cancer Biol 1996 ; 7 : 359-71.
17. Duggan-Keen MF, Keating JP, Stevens FRA, et al. Immunogenetic factors in HPV-associated cervical cancer : Influence on disease progression. Eur J Immunogenet 1996 ; 23 : 275-84.
18. Glew SS, Duggan-Keen M, Cabrera T, Stern PL. HLA class II antigen expression in human papillomavirus-associated cervical cancer. Cancer Res 1992 ; 52 : 4009-16.
19. Wank R, Thomssen C. High risk of squamous cell carcinoma of the cervix with DQw3. Nature 1991 ; 352 : 723-5.
20. Sastre-Garau X, Loste MN, Vincent-Salomon A, et al. Decreased frequency of HLA-DRB1*13 alleles in french population with HPV-positive carcinoma of the cervix. Int J Cancer 1996 ; 69 : 159-64.
21. Nawa A, Nishyama Y, Yamamoto N, et al. Selective suppression of human papillomavirus type 18 mRNA level in HeLa cells by interferon. Biochem Biophys Res Comm 1990 ; 170 : 793-9.
22. Woodworth CG, Lichti U, Simpson S, Evans CH, Di Paolo JA. Leukoregulin and gamma-interferon inhibit human papillomavirus type 16 gene transcription in human papillomavirus-immortalized human cervical cell. Cancer Res 1992 ; 52 : 456-63.
23. Malejczyk J, Malejczyk M, Breitburg F, et al. Progressive growth of human papillomavirus type 16 transformed keratinocytes is associated with an increased release of soluble tumour necrosis factor receptor. Br J Cancer 1996 ; 74 : 234-9.
24. Woodworth CG, Simpson S. Comparative lymphokine secretion by cultured normal human cervical keratinocytes, papillomavirus-immortalized and carcinoma cell lines. Am J Pathol 1993 ; 142 : 1544-55.
25. Petry KU, Richter G. The cellular immune response in cervical tissue adjacent to HPV 16/18 positive CIN. 15th International Papillomavirus Worshop, Brisbane (Australia) 1996 : 212.
26. Malejczyk J, Malejczyk M, Jablonska S, Rogozinski TT, Orth G. Abrogated NK-cell lysis of human papillomavirus (HPV)-16-bearing keratinocytes in patients with pre-cancerous and cancerous HPV-induced anogenital lesions. Int J Cancer 1989 ; 43 : 209-14.
27. Edwards RP, Kuykendall K, Crowley-Nowick P, Partridge EE, Shingleton HM, Mestecky J. T lymphocytes infiltrating advanced grades of cervical neoplasia. Cancer 1995 ; 76 : 1411-5.
28. Greslin I, Bernard B, Biichle S, et al. Cellular immune response in precancerous and cancerous lesions of the cervix. 16th International Papillomavirus Conference, Siena (Italy) 1997 : 353.
29. Knowles G, O'Neil BW, Campo S. Phenotypical characterization of lymphocytes infiltrating regressing papillomas. J Virol 1996 ; 70 : 8451-8.
30. Coleman N, Birley HD, Renton AM, et al. Immunological events in regressing genital warts. Am J Clin Pathol 1994 ; 102 : 768-74.
31. Stanley M, Coleman N, Chamberst M. The host response to lesions induced by human papillomavirus. Vaccine against virally induced cancers. Wiley, Chichester (Ciba Foundation Symposium 187) 1994 : 21-44.
32. Bontkes HJ, de Grujil TD, Walboomers JM, et al. Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions. Br J Cancer 1997 ; 76 : 1353-60.
33. Wu TC, Kurma RJ. Analysis of cytokine profiles in patients with papillomavirus-associated neoplasm. J Natl Cancer Inst 1997 ; 89 : 185-6.
34. Delvenne P, Al-Saleh W, Giannini S, et al. High expression of interleukin-4 in squamous intraepithelial lesions of the uterine cervix. 15th International Papillomavirus Conference, Brisbane (Australia) 1996 : 207.
35. Grubert TA, Shoultz DA, Koutsky LA, Galloway DA. Prevalence and long term persistence of serum antibodies against HPV 6, 16, 18, 31, 33 and 35 in a high risk population. 16th International Papillomavirus Conference, Siena (Italy) 1997 : 251.
36. Leiserowitz GS, Hall KS, Foster CA, et al. Detection of serological neutralizing antibodies against HPV 11 in patients with condyloma acuminata and cervical dysplasia using in vitro assay. Gynecol Oncol 1997 ; 66 : 295-9.
37. Kutteh WH, Hatch KD, Blackwell RE, Mestecky J. Secretory immune system of the female reproductive tract : I. Immunoglobulin and secretory component-containing cells. Obstet Gynecol 1988 ; 71 : 56-60.
38. Dillner L, Fredriksson A, Persson E, et al. Antibodies against antigens in cervical secretions from condyloma patients. J Clin Microbiol 1993 ; 31 : 192-7.
39. Nardelli-Haefliger D, Roden RBS, Benyacoub J, et al. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun 1997 ; 65 : 3328-36.